A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals

Jasper J. Brugts, Aaron Isaacs, Moniek P.M. De Maat, Eric Boersma, Cock M. Van Duijn, K. Martijn Akkerhuis, Andre G. Uitterlinden, Jacqueline C.M. Witteman, Francois Cambien, Claudio Ceconi, Willem Remme, Michel Bertrand, Toshiharu Ninomiya, Stephen Harrap, John Chalmers, Stephen MacMahon, Kim Fox, Roberto Ferrari, Maarten L. Simoons, A. H.Jan Danser

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Aims: To investigate whether genetic variation in the renin-angiotensin- aldosterone system (RAAS) and kallikrein-bradykinin pathways is related to hypertension and blood pressure (BP) response to angiotensin-converting enzyme (ACE) inhibitor therapy in stable coronary artery disease (CAD) patients. Methods and Results: In 8907 stable CAD patients from the EUROPA trial, 52 haplotype-tagging single-nucleotide polymorphisms (SNPs) in 12 candidate genes within the RAAS and kallikrein-bradykinin pathways were investigated for association with hypertension (defined as BP 160/95 mmHg or use of antihypertensives) and BP response to ACE inhibitors, during a 4-week run-in period. All analyses were adjusted for age, sex, body mass index and creatinine clearance and corrected for multiple testing. Results: Hypertension was present in 28.3% of the patients (n = 2526); median BP reduction after perindopril was 10/4 mmHg. Four polymorphisms, located in the ACE (rs4291), angiotensinogen (rs5049) and (pro)renin receptor (rs2968915; rs5981008) genes were significantly associated with hypertension in two vascular disease populations of CAD (EUROPA) and cerebrovascular disease (PROGRESS; n = 3571). A cumulative profile demonstrated a stepwise increase in the prevalence of hypertension, mounting to a 2-3-fold increase (P for trend <0.001). Similar associations on hypertension were observed for angiotensinogen in a healthy population (n = 2197). In addition, genetic polymorphisms were identified that significantly modified the BP reduction by ACE inhibitor therapy; however, the observed BP differences were small and did not remain significant after permutation analysis. Conclusion: This large genetic association study identified genetic determinants of hypertension in three cohorts of patients with vascular disease and healthy individuals.

Original languageEnglish
Pages (from-to)509-519
Number of pages11
JournalJournal of hypertension
Volume29
Issue number3
DOIs
Publication statusPublished - Mar 1 2011
Externally publishedYes

Fingerprint

Enzyme Therapy
Vascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Blood Pressure
Hypertension
Coronary Artery Disease
Angiotensinogen
Kallikreins
Bradykinin
Renin-Angiotensin System
Perindopril
Cerebrovascular Disorders
Genetic Association Studies
Peptidyl-Dipeptidase A
Genetic Polymorphisms
Pharmacogenomic Testing
Renin
Haplotypes
Antihypertensive Agents
Population

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. / Brugts, Jasper J.; Isaacs, Aaron; De Maat, Moniek P.M.; Boersma, Eric; Van Duijn, Cock M.; Akkerhuis, K. Martijn; Uitterlinden, Andre G.; Witteman, Jacqueline C.M.; Cambien, Francois; Ceconi, Claudio; Remme, Willem; Bertrand, Michel; Ninomiya, Toshiharu; Harrap, Stephen; Chalmers, John; MacMahon, Stephen; Fox, Kim; Ferrari, Roberto; Simoons, Maarten L.; Danser, A. H.Jan.

In: Journal of hypertension, Vol. 29, No. 3, 01.03.2011, p. 509-519.

Research output: Contribution to journalArticle

Brugts, JJ, Isaacs, A, De Maat, MPM, Boersma, E, Van Duijn, CM, Akkerhuis, KM, Uitterlinden, AG, Witteman, JCM, Cambien, F, Ceconi, C, Remme, W, Bertrand, M, Ninomiya, T, Harrap, S, Chalmers, J, MacMahon, S, Fox, K, Ferrari, R, Simoons, ML & Danser, AHJ 2011, 'A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals', Journal of hypertension, vol. 29, no. 3, pp. 509-519. https://doi.org/10.1097/HJH.0b013e328341d117
Brugts, Jasper J. ; Isaacs, Aaron ; De Maat, Moniek P.M. ; Boersma, Eric ; Van Duijn, Cock M. ; Akkerhuis, K. Martijn ; Uitterlinden, Andre G. ; Witteman, Jacqueline C.M. ; Cambien, Francois ; Ceconi, Claudio ; Remme, Willem ; Bertrand, Michel ; Ninomiya, Toshiharu ; Harrap, Stephen ; Chalmers, John ; MacMahon, Stephen ; Fox, Kim ; Ferrari, Roberto ; Simoons, Maarten L. ; Danser, A. H.Jan. / A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. In: Journal of hypertension. 2011 ; Vol. 29, No. 3. pp. 509-519.
@article{ffc4d5aecac44cf5b06a98303570d6bb,
title = "A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals",
abstract = "Aims: To investigate whether genetic variation in the renin-angiotensin- aldosterone system (RAAS) and kallikrein-bradykinin pathways is related to hypertension and blood pressure (BP) response to angiotensin-converting enzyme (ACE) inhibitor therapy in stable coronary artery disease (CAD) patients. Methods and Results: In 8907 stable CAD patients from the EUROPA trial, 52 haplotype-tagging single-nucleotide polymorphisms (SNPs) in 12 candidate genes within the RAAS and kallikrein-bradykinin pathways were investigated for association with hypertension (defined as BP 160/95 mmHg or use of antihypertensives) and BP response to ACE inhibitors, during a 4-week run-in period. All analyses were adjusted for age, sex, body mass index and creatinine clearance and corrected for multiple testing. Results: Hypertension was present in 28.3{\%} of the patients (n = 2526); median BP reduction after perindopril was 10/4 mmHg. Four polymorphisms, located in the ACE (rs4291), angiotensinogen (rs5049) and (pro)renin receptor (rs2968915; rs5981008) genes were significantly associated with hypertension in two vascular disease populations of CAD (EUROPA) and cerebrovascular disease (PROGRESS; n = 3571). A cumulative profile demonstrated a stepwise increase in the prevalence of hypertension, mounting to a 2-3-fold increase (P for trend <0.001). Similar associations on hypertension were observed for angiotensinogen in a healthy population (n = 2197). In addition, genetic polymorphisms were identified that significantly modified the BP reduction by ACE inhibitor therapy; however, the observed BP differences were small and did not remain significant after permutation analysis. Conclusion: This large genetic association study identified genetic determinants of hypertension in three cohorts of patients with vascular disease and healthy individuals.",
author = "Brugts, {Jasper J.} and Aaron Isaacs and {De Maat}, {Moniek P.M.} and Eric Boersma and {Van Duijn}, {Cock M.} and Akkerhuis, {K. Martijn} and Uitterlinden, {Andre G.} and Witteman, {Jacqueline C.M.} and Francois Cambien and Claudio Ceconi and Willem Remme and Michel Bertrand and Toshiharu Ninomiya and Stephen Harrap and John Chalmers and Stephen MacMahon and Kim Fox and Roberto Ferrari and Simoons, {Maarten L.} and Danser, {A. H.Jan}",
year = "2011",
month = "3",
day = "1",
doi = "10.1097/HJH.0b013e328341d117",
language = "English",
volume = "29",
pages = "509--519",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals

AU - Brugts, Jasper J.

AU - Isaacs, Aaron

AU - De Maat, Moniek P.M.

AU - Boersma, Eric

AU - Van Duijn, Cock M.

AU - Akkerhuis, K. Martijn

AU - Uitterlinden, Andre G.

AU - Witteman, Jacqueline C.M.

AU - Cambien, Francois

AU - Ceconi, Claudio

AU - Remme, Willem

AU - Bertrand, Michel

AU - Ninomiya, Toshiharu

AU - Harrap, Stephen

AU - Chalmers, John

AU - MacMahon, Stephen

AU - Fox, Kim

AU - Ferrari, Roberto

AU - Simoons, Maarten L.

AU - Danser, A. H.Jan

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Aims: To investigate whether genetic variation in the renin-angiotensin- aldosterone system (RAAS) and kallikrein-bradykinin pathways is related to hypertension and blood pressure (BP) response to angiotensin-converting enzyme (ACE) inhibitor therapy in stable coronary artery disease (CAD) patients. Methods and Results: In 8907 stable CAD patients from the EUROPA trial, 52 haplotype-tagging single-nucleotide polymorphisms (SNPs) in 12 candidate genes within the RAAS and kallikrein-bradykinin pathways were investigated for association with hypertension (defined as BP 160/95 mmHg or use of antihypertensives) and BP response to ACE inhibitors, during a 4-week run-in period. All analyses were adjusted for age, sex, body mass index and creatinine clearance and corrected for multiple testing. Results: Hypertension was present in 28.3% of the patients (n = 2526); median BP reduction after perindopril was 10/4 mmHg. Four polymorphisms, located in the ACE (rs4291), angiotensinogen (rs5049) and (pro)renin receptor (rs2968915; rs5981008) genes were significantly associated with hypertension in two vascular disease populations of CAD (EUROPA) and cerebrovascular disease (PROGRESS; n = 3571). A cumulative profile demonstrated a stepwise increase in the prevalence of hypertension, mounting to a 2-3-fold increase (P for trend <0.001). Similar associations on hypertension were observed for angiotensinogen in a healthy population (n = 2197). In addition, genetic polymorphisms were identified that significantly modified the BP reduction by ACE inhibitor therapy; however, the observed BP differences were small and did not remain significant after permutation analysis. Conclusion: This large genetic association study identified genetic determinants of hypertension in three cohorts of patients with vascular disease and healthy individuals.

AB - Aims: To investigate whether genetic variation in the renin-angiotensin- aldosterone system (RAAS) and kallikrein-bradykinin pathways is related to hypertension and blood pressure (BP) response to angiotensin-converting enzyme (ACE) inhibitor therapy in stable coronary artery disease (CAD) patients. Methods and Results: In 8907 stable CAD patients from the EUROPA trial, 52 haplotype-tagging single-nucleotide polymorphisms (SNPs) in 12 candidate genes within the RAAS and kallikrein-bradykinin pathways were investigated for association with hypertension (defined as BP 160/95 mmHg or use of antihypertensives) and BP response to ACE inhibitors, during a 4-week run-in period. All analyses were adjusted for age, sex, body mass index and creatinine clearance and corrected for multiple testing. Results: Hypertension was present in 28.3% of the patients (n = 2526); median BP reduction after perindopril was 10/4 mmHg. Four polymorphisms, located in the ACE (rs4291), angiotensinogen (rs5049) and (pro)renin receptor (rs2968915; rs5981008) genes were significantly associated with hypertension in two vascular disease populations of CAD (EUROPA) and cerebrovascular disease (PROGRESS; n = 3571). A cumulative profile demonstrated a stepwise increase in the prevalence of hypertension, mounting to a 2-3-fold increase (P for trend <0.001). Similar associations on hypertension were observed for angiotensinogen in a healthy population (n = 2197). In addition, genetic polymorphisms were identified that significantly modified the BP reduction by ACE inhibitor therapy; however, the observed BP differences were small and did not remain significant after permutation analysis. Conclusion: This large genetic association study identified genetic determinants of hypertension in three cohorts of patients with vascular disease and healthy individuals.

UR - http://www.scopus.com/inward/record.url?scp=79951673075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951673075&partnerID=8YFLogxK

U2 - 10.1097/HJH.0b013e328341d117

DO - 10.1097/HJH.0b013e328341d117

M3 - Article

C2 - 21157371

AN - SCOPUS:79951673075

VL - 29

SP - 509

EP - 519

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 3

ER -